Crizotinib Capsules

Name: Crizotinib Capsules
Brand: EBIO GLOBAL TRADE LLP
Price: 17500.0 INR
Availability: InStock

Price 17500.0 INR/ Strip

Get a Price/Quote

MOQ : 58 Strips

Crizotinib Capsules Specification

Dosage Form
Capsules

Salt Composition
Crizotinib

Indication
Non-Small Cell Lung Cancer (NSCLC) with ALK or ROS1 mutations

Feature
Targeted therapy for ALK and ROS1 positive lung cancers

Ingredients
Crizotinib 250 mg and excipients

Application
Oral use for cancer treatment

Physical Color/Texture
Capsule form, specific color not visible

Storage Instructions
Store below 30C (86F), keep in original package to protect from moisture

Shelf Life
Check pack for expiry, generally 24-36 months from manufacturing

Prescription/Non-Prescription
Prescription

Marketed By
Pfizer Ltd.

Packaging Size
60 capsules per box

Type of Medicine
Oncology / Antineoplastic

Administration Route
Oral

Strength
250 mg per capsule

Brand Name
Crizalk

Storage Condition
Keep away from children and moisture

About Crizotinib Capsules

Crizalk (Crizotinib Capsules 250 mg) by Pfizer Ltd. stands out as a peerless solution for targeted cancer therapy. This distinguished product has earned favorable reviews for its efficacy in treating Non-Small Cell Lung Cancer (NSCLC) with ALK or ROS1 mutations. The latest formulation, containing 60 capsules per box, is world-class in oncology care. Specially designed for oral administration, Crizalk ensures quality and safety by requiring prescription use and storage in a moisture-free environment. Experience specialized support in cancer management with this outstanding innovation.

Application and Usage Characteristics

Crizotinib Capsules are primarily used in oncology, specifically for treating NSCLC that tests positive for ALK or ROS1 mutations. The application media is oral, with patients ingesting capsules as prescribed. The site of application is systemic, as the medication targets cancer cells throughout the body. This makes it an essential tool in the fight against specific lung cancers, offering patients access to targeted therapy that focuses on the genetic drivers of their disease.

Domestic and Export Market Excellence

Crizotinib Capsules enjoy premium status in India's main domestic healthcare market, with stock ready for prompt fulfillment. They are equally distinguished in international export markets, where their world-class quality supports advanced oncology protocols. Bulk supply options are available for global distributors, making expenditure on proven, quality-assured therapy a wise investment. Certifications and compliance with industry standards reinforce confidence for hospitals, exporters, and traders seeking reliable antineoplastic medications.

FAQ's of Crizotinib Capsules:

Q: How should Crizalk Crizotinib Capsules be administered?

A: Crizalk is administered orally, typically as directed by a healthcare professional. It is important to take the capsules at the same time every day, following your doctor's specific instructions for dose and duration.

Q: What is the main benefit of using Crizotinib Capsules?

A: The main benefit of Crizotinib Capsules is their targeted action against ALK or ROS1 mutation-positive Non-Small Cell Lung Cancer, offering more personalized and effective cancer therapy.

Q: Where should Crizotinib Capsules be stored to maintain efficacy?

A: Store Crizotinib Capsules below 30C (86F) in the original package, away from moisture and out of reach of children, to ensure they remain effective until their expiry date.

Q: When should patients start using Crizalk for lung cancer?

A: Patients should begin using Crizalk only after being diagnosed with NSCLC containing ALK or ROS1 mutations and upon prescription by a qualified healthcare provider.

Q: What certifications support the quality of Crizotinib Capsules?

A: Crizotinib Capsules are marketed by Pfizer Ltd., a globally recognized company, and comply with all necessary certifications and export regulations, ensuring reliability and trust for both domestic and international clients.

Tell us about your requirement